CoChat
Sign Up
Cited by 967Hormonal and reproductive studiesAdrenal Hormones and DisordersGrowth Hormone and Insulin-like Growth Factors

The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.

Testosterone dose-response relationships in healthy young men

Bhasin, Shalender, Woodhouse, Linda, Casaburi, Richard, Singh, Atam B., Bhasin, Dimple, Berman, Nancy, Chen, Xianghong, Yarasheski, Kevin E., Magliano, Lynne, Dzekov, Connie, Dzekov, Jeanne, Bross, Rachelle, Phillips, Jeffrey, Sinha-Hikim, Indrani, Shen, Ruoquing, Storer, Thomas W.·2001·American Journal of Physiology-Endocrinology and Metabolism
DOI 10.1152/ajpendo.2001.281.6.e1172
Open this paper in CoChat — free account

Abstract

Testosterone increases muscle mass and strength and regulates other physiological processes, but we do not know whether testosterone effects are dose dependent and whether dose requirements for maintaining various androgen-dependent processes are similar. To determine the effects of graded doses of testosterone on body composition, muscle size, strength, power, sexual and cognitive functions, prostate-specific antigen (PSA), plasma lipids, hemoglobin, and insulin-like growth factor I (IGF-I) levels, 61 eugonadal men, 18-35 yr, were randomized to one of five groups to receive monthly injections of a long-acting gonadotropin-releasing hormone (GnRH) agonist, to suppress endogenous testosterone secretion, and weekly injections of 25, 50, 125, 300, or 600 mg of testosterone enanthate for 20 wk. Energy and protein intakes were standardized. The administration of the GnRH agonist plus graded doses of testosterone resulted in mean nadir testosterone concentrations of 253, 306, 542, 1,345, and 2,370 ng/dl at the 25-, 50-, 125-, 300-, and 600-mg doses, respectively. Fat-free mass increased dose dependently in men receiving 125, 300, or 600 mg of testosterone weekly (change +3.4, 5.2, and 7.9 kg, respectively). The changes in fat-free mass were highly dependent on testosterone dose (P = 0.0001) and correlated with log testosterone concentrations (r = 0.73, P = 0.0001). Changes in leg press strength, leg power, thigh and quadriceps muscle volumes, hemoglobin, and IGF-I were positively correlated with testosterone concentrations, whereas changes in fat mass and plasma high-density lipoprotein (HDL) cholesterol were negatively correlated. Sexual function, visual-spatial cognition and mood, and PSA levels did not change significantly at any dose. We conclude that changes in circulating testosterone concentrations, induced by GnRH agonist and testosterone administration, are associated with testosterone dose- and concentration-dependent changes in fat-free mass, muscle size, strength and power, fat mass, hemoglobin, HDL cholesterol, and IGF-I levels, in conformity with a single linear dose-response relationship. However, different androgen-dependent processes have different testosterone dose-response relationships.

Overview

Integrity signals

Registry

Crossref · 10.1152/ajpendo.2001.281.6.e1172

Cites

53 of 53 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 52 references

Research works printed but not linked: 12

  1. Bagatell CJ, 1994, J Clin Endocrinol Metab, 78, 711
  2. Bhasin S, 1997, J Clin Endocrinol Metab, 82, 3
  3. Bhasin S, 1997, J Clin Endocrinol Metab, 82, 407
  4. Brodsky IG, 1996, J Clin Endocrinol Metab, 81, 3469
  5. Dobs AS, 1999, J Clin Endocrinol Metab, 84, 3469
  6. Gillum RF, 1996, Stroke, 27, 1910
  7. Katznelson L, 1996, J Clin Endocrinol Metab, 81, 4358
  8. Mauras N, 1998, J Clin Endocrinol Metab, 83, 1886
  9. Sinha-Hikim I, 1998, J Clin Endocrinol Metab, 83, 1312
  10. Snyder PJ, 2000, J Clin Endocrinol Metab, 85, 2670
  11. Snyder PJ, 1999, J Clin Endocrinol Metab, 84, 2647
  12. Wang C, 2000, J Clin Endocrinol Metab, 85, 2839

Cited by

Sorted by citations

Related

See all

Metadata

Authors
Bhasin, S., Woodhouse, L., Casaburi, R., Singh, A. B., Bhasin, D., Berman, N., Chen, X., Yarasheski, K. E., Magliano, L., Dzekov, C., Dzekov, J., Bross, R., Phillips, J., Sinha-Hikim, I., Shen, R., & Storer, T. W.
Affiliations
  • Charles R. Drew University of Medicine and Science (US)
  • University of California, Los Angeles (US)
  • Washington University in St. Louis (US)
  • El Camino College (US)
  • Division of Endocrinology, Metabolism, and Molecular Medicine, Charles R. Drew University of Medicine and Science, Los Angeles 90059;
ORCID
Venue
American Journal of Physiology-Endocrinology and Metabolism
Publisher
American Physiological Society
Published
2001-12-01
Volume
281
Issue
6
Pages
E1172-E1181
ISSN
  • 0193-1849 (ISSN-L)
  • 1522-1555
DOI
10.1152/ajpendo.2001.281.6.e1172
OpenAlex
W2109494488
Cited by
967
References
52
Citations by year
2026: 32 · 2025: 36 · 2024: 35 · 2023: 38 · 2022: 54 · 2021: 29 · 2020: 34 · 2019: 39 · 2018: 36 · 2017: 41 · 2016: 41 · 2015: 29 · 2014: 39 · 2013: 40 · 2012: 34
FWCI
23.21
Type
journal article
Language
en
Open access
closed
Locations
  • American Journal of Physiology-Endocrinology and Metabolism (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Institutes of Health (5p41rr000954-34, ODP 1397)
  • U.S. Public Health Service (00954, MO-00425)
  • National Institute on Aging (1RO1-AG-14369, R01AG014369)
  • National Institute of Diabetes and Digestive and Kidney Diseases (1RO1 DK-49296, R01DK049296, 1RO1-DK-59297-01)
  • National Center for Research Resources (P20 RR 11145-01, G12 RR 03026, P41-RR000954, G12RR003026, P20RR011145)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Growth Hormone and Insulin-like Growth Factors
Keywords
testosterone, dose-response relationship, testosterone enanthate, GnRH agonist, testosterone replacement therapy, fat-free mass, muscle strength, muscle power, muscle volume, hemoglobin, HDL cholesterol, insulin-like growth factor I, prostate-specific antigen, sexual function, cognitive function, young men
MeSH terms
Adult, Androgen Antagonists, Body Composition, Body Water, Dose-Response Relationship, Drug, Double-Blind Method, Humans, Insulin-Like Growth Factor I, Luteinizing Hormone, Gonadotropin-Releasing Hormone, Male, Nutritional Physiological Phenomena, Sexual Behavior, Testosterone, Exercise, Muscle, Skeletal

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review